| Name | Title | Contact Details |
|---|---|---|
Joseph Donato |
Vice President, Human Resources and Organizational Development | Profile |
Joseph Donato |
Vice President - Human Resources and Organizational Development | Profile |
Lawnwood Regional Medical Center & Heart Institute is a Fort Pierce, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Medwatch is a Lake Mary, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ARISTOI is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since its beginning in 2007 as a technical staffing and business solutions group in Annapolis, Md., Syndicus has evolved into a highly respected technical staffing and consulting solutions group that provides talent and solutions for three focus areas: Health Information Technology, Life Sciences Solutions and Technology Services. We pride ourselves in partnering with top subject matter experts who ensure candidates, consultants and solutions meet clients' specialized needs. In 2012, Syndicus achieved both a full national accreditation with the Management Services Organization Accreditation Program (MSOAP) from the Electronic Healthcare Network Accreditation Commission (EHNAC) and the MSO State Designation from the Maryland Health Care Commission (MHCC). The two certifications enable Syndicus and its electronic health records (EHR) hosted solutions provider eCast Corporation to continue working with Maryland healthcare providers on EHR adoption efforts – and subsequent achievement of Meaningful Use.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.